Human-Organoid Models: Accomplishments to Salvage Test-Animals
Ranjna C Dutta* and Aroop K Dutta
ExCel Matrix Biological Devices Private Limited, Tarnaka, Hyderabad, Telangana, India
- *Corresponding Author:
- Ranjana C Dutta
ExCel Matrix Biological Devices Private Limited
Tarnaka, Hyderabad-500 017
E-mail: [email protected]
Received date: Mar 12, 2016; Accepted date: May 18, 2016; Published date: May 25, 2016
Citation: Dutta RC, Dutta AK (2016) Human-Organoid Models: Accomplishments to Salvage Test-Animals. J Biomed Eng Med Devic 1: 110.
Copyright: © 2016 Dutta RC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Late stage attritions in drug discovery are costly and consuming. Improbable response of test molecules acquired in non-human systems is attributed to be the major cause of clinical failures. While conventional in vitro methods of drug discovery do not truly represent the human system, the animal models used for in vivo validation are also genetically and phenotypically distant from humans. However, recent developments in organoid culture are motivating and elevate hopes for replacing test animals with artificial human tissue models. Possibility of creating functional tissue ex vivo has a potential to revolutionize the way human therapeutics is perceived. Not only will it bridge the gap between drug development and its clinical efficacy but also help strategizing regenerative medicine. Successful human-tissue surrogates would liberate test animals or at least minimize their use for research purposes. Potential drug candidates tested on human-tissue equivalents are expected to generate clinically much more relevant data. Here we deliberate upon the options and possibilities of accomplishing human organoid models for in vitro testing and their significance in therapeutics.